Company

Bank

Analyst

Coverage

Opinion

Wk chg

4/25 cls

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)

Brinson Patrick

Christopher James

New

Market outperform

-4%

$8.01

James initiated coverage with a $15 target. He expects upside from data from the Phase IIa OPuS-1 trial of BCX4161 to treat hereditary angioedema (HAE). He expects top-line data in June. The product is a selective inhibitor of plasma kallikrein that subsequently suppresses bradykinin production. James believes that a safe, effective oral HAE therapy could exceed sales of $2.2B in the U.S. and EU.

Cesca Therapeutics Inc. (NASDAQ:KOOL)

Maxim Group

Jason Kolbert

New

Buy

28%

$1.91